Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
Status:
Completed
Trial end date:
2021-04-23
Target enrollment:
Participant gender:
Summary
The purpose of this prospective, Phase 2, multicenter, blinded, randomized placebo controlled
study is to demonstrate that early treatment with mavrilimumab prevents progression of
respiratory failure in patients with severe COVID-19 pneumonia and clinical and biological
features of hyper-inflammation.